25181-50-4

Usage

Uses

Used in Pharmaceutical Industry:
3-aminopiperidine-2,6-dione hydrochloride is used as a pharmaceutical intermediate for the development of various drugs. It plays a vital role in the synthesis of medications targeting different therapeutic areas, such as central nervous system disorders, cardiovascular diseases, and pain management.
Used in Organic Synthesis:
In the field of organic synthesis, 3-aminopiperidine-2,6-dione hydrochloride is used as an intermediate for the production of various chemical compounds. Its unique structure allows for a wide range of reactions, making it a valuable building block in the creation of complex organic molecules.
Used in Laboratory Research and Development:
3-aminopiperidine-2,6-dione hydrochloride is also utilized in laboratory research and development processes. It is an essential component in the design and synthesis of new molecules for potential applications in various industries, including pharmaceuticals, agrochemicals, and materials science.
Used in Chemical Production Processes:
In the chemical production industry, 3-aminopiperidine-2,6-dione hydrochloride is employed as a key intermediate in the manufacturing of various chemicals. Its ability to participate in a diverse set of reactions makes it a valuable asset in the production of specialty chemicals and advanced materials.

Upstream product

• 15387-45-8 Boc-Gln-ONp 
• 56-85-9 L-glutamine 
• 151367-92-9 L-tert-butyl N-[2,6-dioxohexahydro-3-pyridinyl] Carbamate 

Relevant academic research and scientific papers

Preparation method of 3-amino-2,6-piperidinedione hydrochloride

The invention discloses a preparation method of 3-amino-2,6-piperidinedione hydrochloride. The method comprises the following steps that (1) L-glutamine is protected in an alkaline medium to obtain N-tert-butyl oxyformyl-L-glutamine; (2) under the anhydrous condition, the N-tert-butyl oxyformyl-L-glutamine obtained in step (1) and N,N-carbonyldiimidazole are subjected to cyclization under catalysis of 4-dimethylamino pyridine to obtain N-tert-butyl oxyformyl-3-amino-2,6-piperidinedione; (3) the N-tert-butyl oxyformyl-3-amino-2,6-piperidinedione obtained in step (2) is subjected to deprotectionin an acid medium, hydrochloride is formed, and the 3-amino-2,6-piperidinedione hydrochloride is obtained. The target product, namely the 3-amino-2,6-piperidinedione hydrochloride, is obtained by three steps including protection, cyclization, deprotection and hydrochloride forming, and the obtained product is high in purity and stable in quality. According to the preparation method, only three steps are needed in the synthesis process, the path is simple, the reaction conditions are mild, a high-pressure hydrogenation condition is not needed, the cost is low, and industrialization is easy toachieve.

Synthesis of new hydantoins bearing glutarimide or succinimide moiety and their evaluation for cell differentiation-inducing and anti-angiogenic activities

Several derivatives of hydantoin containing glutarimide or succinimide at the 3-position were synthesized. The new hydantoin derivatives had a structure similar to that of thalidomide, and so may possess activity similar to that of thalidomide and/or its

Design, synthesis and biological evaluation of new thalidomide analogues as TNF-α and IL-6 production inhibitors

Several thalidomide analogues were synthesized and compared to thalidomide and its more active analogue, lenalidomide, for their ability to inhibit the production of the pro-inflammatory cytokine tumour necrosis factor (TNF)-α and interleukin (IL)-6 by LPS-activated peripheral blood mononuclear cells (PBMCs). Among these compounds, two analogues containing sulfonyl group displayed interesting downregulation of TNF-α and IL-6 production.